ALPMF (Astellas Pharma) Momentum Rank: 4 (As of Sep. 05, 2026) — 33% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ALPMF Astellas Pharma Inc ALPMF
81 GF Score
Price $15.10
GF Value $15.38
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Astellas Pharma Momentum Rank?

Astellas Pharma ALPMF +1.96% 81 Momentum Rank is 4 as of Sep. 05, 2026, which is 33% above its 10-year median of 3.00. GuruFocus rates ALPMF with a GF Score™ of 81/100 and a GF Value™ of $15.38 (Fairly Valued). The stock has 5 warning signs investors should review.

Astellas Pharma has the Momentum Rank of 4.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Astellas Pharma Momentum Rank Related Terms

ALPMF vs LLY, JNJ, ABBV: Momentum Rank Comparison

For the Drug Manufacturers - General subindustry, Astellas Pharma's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Astellas Pharma Momentum Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Momentum Rank falls into.


ALPMF
81GF Score
Astellas Pharma Inc ALPMF
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 4 mean?
Astellas Pharma (ALPMF) has a Momentum Rank of 4 as of Sep. 05, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Astellas Pharma and its competitors. This is 33% above median its historical median of 3.00. Over the past decade, Astellas Pharma's Momentum Rank has ranged from 1.00 to 10.00.
Is Astellas Pharma's Momentum Rank too high?
Astellas Pharma's current Momentum Rank of 4 is 33% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, Astellas Pharma has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Momentum Rank compare to LLY and JNJ?
Astellas Pharma's Momentum Rank of 4 can be compared against companies in the Drug Manufacturers industry. Historically, Astellas Pharma's own Momentum Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Drug Manufacturers company?
A good Momentum Rank depends on the Drug Manufacturers industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Astellas Pharma and its competitors. Astellas Pharma's current Momentum Rank is 4, which is 33% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $15.38, compared to a current price of $15.10 — trading 1.8% below its estimated fair value. The current Momentum Rank is 4, which is 33% above median its 10-year median of 3.00. Astellas Pharma's overall GF Score™ is 81/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Momentum Rank is 4 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astellas Pharma (ALPMF) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued. The current stock price of $15.10 is trading 1.8% below its estimated GF Value™ of $15.38. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for ALPMF:

  • Momentum Rank: 4 (33% above median its 10-year median of 3.00)
  • GF Value™: $15.38 vs. price of $15.10 (1.8% below fair value)
  • GF Score™: 81/100 with 5 warning signs

No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
81GF Score

Get the complete analysis for ALPMF

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.10
Price
$15.38
GF Value